Bausch Health Acknowledges XIFAXAN's Selection for Medicare Negotiation

Bausch Health Companies Inc. and its division, Salix Pharmaceuticals, have recognized XIFAXAN® (rifaximin) 550 mg tablets' selection by the Centers for Medicare and Medicaid Services (CMS) for the Inflation Reduction Act's Drug Price Negotiation program. This inclusion will affect pricing beginning in 2027.

The company anticipates engaging in open discussions with CMS to present the value of XIFAXAN® to the healthcare system. Recommendations from significant liver disease associations, AASLD and EASL, support XIFAXAN®'s utilization, acknowledging it with the highest recommendation grade.

Bausch Health is committed to advocating for patient access to essential medications and encourages ongoing innovation in the healthcare sector.